Measuring the Cost-Effectiveness of Cancer Care  Measuring the
Cost-Effectiveness of Cancer Care   Traditionally, the
assessment of new therapeutic strategies for cancer has relied
almost solely on safety and clinical efficacy. Recent concerns
over escalating US health-care expenditures and with optimizing
patient outcomes have led to increased interest in the economic
assessment of cancer therapies as a secondary objective in the
evaluation of such treatments. In particular, attention has
focused on the efficiency of resource allocation in health-care
delivery. New economic measures are increasingly being
integrated into cancer clinical trials to assess the cost-
effectiveness of therapy and patients' quality of life after
treatment. These measures will improve the assessment of both
the costs and benefits of cancer treatment strategies.  Given
the growing recognition by clinicians, patients, and health-care
financing organizations of resource constraints on the provision
of health-care services, economic eva